Yesintek Gets FDA Approval as the sixth Biosimilar to Stelara

Indian Generic Medicines17 Dec, 2024Health

Yesintek, developed by Biocon Biologics, has received FDA approval as the sixth biosimilar to Stelara (Ustekinumab). This groundbreaking approval provides a cost-effective treatment alternative for conditions like Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Yesintek's approval marks a significant step toward expanding patient access to advanced biologic therapies, ensuring affordability without compromising quality. With its proven efficacy, Yesintek is set to benefit patients seeking reliable biosimilar options. Biocon Biologics continues to lead the way in delivering innovative healthcare solutions worldwide. Stay informed about the latest FDA approvals and biosimilar advancements.